A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Simvastatin 40 mg Film-coated Tablets and Reference Product (ZOCOR) in healthy Thai Volunteers under Fasting Conditions (Pilot Study)

International Bio Service Co., Ltd.0 个研究点目标入组 12 人开始时间: 2021年8月10日最近更新: 2024年8月19日

适应症

试验速览

阶段: 1 期
状态: 尚未招募
发起方
入组人数: 12

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 Years 至 55 Years（—）
性别: All

入选标准

•1. Healthy Thai male or female subjects between the ages of 18 to 55 years., 2. Body mass index between 18.0 to 30.0 kg/m2., 3. Normal laboratory values, including vital signs and physical examination, for all parameters in clinical laboratory tests at screening. Any abnormalities from the normal or reference range will be carefully considered clinically relevant by the physician as individual cases, documented in study files prior to enrolling the subject in this study., 4. Non-pregnant woman (negative pregnancy test) and not currently breast feeding., 5. Female subjects abstain from either hormonal methods of contraception (including oral or transdermal contraceptives, injectable progesterone, progestin subdermal implants, progesterone-releasing IUDs, postcoital contraceptive methods) or hormone replacement therapy for at least 28 days prior to check-in in Period 1. Injectable contraceptives e.g. Depo-Provera will be discontinued at least 6 months prior to check-in in Period 1. Subjects agree to use acceptable non-hormonal contraceptive methods such as condom, diaphragm, foams, jellies or abstinence for at least 14 days prior to check-in in Period 1 until 7 days after the end of study in Period 2. Female subjects of non-childbearing potential must meet at least one of the following criteria prior to check-in in Period 1: Postmenopausal for at least 1 year or Surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) at least 6 months., 6. Male subjects who are willing or able to use effective contraceptive e.g. condom or abstinence after check-in in Period 1 until 7 days after the end of study in Period 2., 7. Have voluntarily given written informed consent (signed and dated) by the subject prior to participating in this study.

排除标准

•1. History of allergic reaction or hypersensitivity to simvastatin or to any excipients of tablet, 2. History or evidence of clinically significant renal, hepatic, gastrointestinal, hematological (e.g. anemia), endocrine (e.g. hyper-/hypothyroid, diabetes), pulmonary or respiratory (e.g. asthma), cardiovascular (e.g. hyper-/hypotension), psychiatric (e.g. depression), neurologic (e.g. convulsant), allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing) or any significant ongoing chronic medical illness, 3. History or evidence of muscular disease e.g. muscle pain, tenderness, weakness, myopathy or rhabdomyolysis, 4. Have high risk for coronavirus infection based on risk assessment questionnaire or diagnosed as confirmed case of COVID-19, 5. History about administration of first dose or second dose of COVID-19 vaccine within 30 days prior to check-in in each Period., 6. History of problems with swallowing tablet or capsule, 7. History or evidence of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption, 8. History of sensitivity to heparin or heparin-induced thrombocytopenia, 9. Any condition possibly affecting drug absorption e.g. gastrectomy, enterectomy, gastritis or duodenal or gastric ulceration other than appendectomy, 10. History of diarrhea or vomiting within 24 hours prior to check-in in each period, 11. 12-lead ECG demonstrating QTc more than 450 msec, a QRS interval more than 120 msec or with an abnormality considered clinically significant at screening. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG will be repeated two more times and the average of the three QTc or QRS values will be used to determine the subjects eligibility., 12. Investigation with blood sample shows positive test for HBsAg., 13. History or evidence of drug addict or investigation with urine sample shows a positive test for drug of abuse (morphine, marijuana or methamphetamine), 14. History or evidence of liver disease or renal impairment, 15. Creatine kinase (CK) levels more than or equal to1.5 times of upper normal limit of reference range (unless explained by exercise) at screening laboratory test, 16. Have renal creatinine clearance (CLcr) less than 30 mL/min based on serum creatinine results, using glomerular filtration rate (GFR; Cockcroft-Gault formula), at the screening laboratory test, 17. Abnormal liver function, more than or equal to 1.5 times of upper normal limit of reference range for ALT, AST or bilirubin levels at screening laboratory test, 18. History or evidence of habitual use of tobacco or nicotine containing products and cannot abstain for at least 48 hours prior to check-in in Period 1 and continued for entire duration of the study, 19. History or evidence of alcoholism or harmful use of alcohol (less than 2 years) i.e., alcohol consumption of more than 14 standard drinks per week for men and 7 standard drinks per week for women (A standard drink is defined as 360 mL of beer or 150 mL of wine or 45 mL of 40% distilled spirits, such as rum, whisky, brandy etc.), 20. History or evidence of alcohol consumption or alcohol-containing products and cannot abstain for at least 48 hours prior to check-in in Period 1 and continued for entire duration of the study or alcohol breath test shows positive result. In case of alcohol breath test result represents the alcohol concentration range of 1 - 10 mg% BAC and the physician carefully consid

研究者

发起方

International Bio Service Co., Ltd.

相似试验

尚未招募

1 期

A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Pregabalin 50 mg Capsules and Reference Product (LyricaTM) in Healthy Thai Volunteers under Fasting ConditionsHealthy Thai Volunteers

TCTR20240427011International Bio Service30

尚未招募

1 期

Bioequivalence Study of Levetiracetam 500 mg Film-coated Tablets in Healthy Thai VolunteersHealthy volunteerLevetiracetam, Bioequivalence Study, Healthy Thai Volunteer

TCTR20230905002International Bio Service Co., Ltd.26

尚未招募

1 期

A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Generic Donepezil Hydrochloride 10 mg Orodispersible Tablets and Reference Product (Aricept Evess 10 mg) in Healthy Thai Volunteers under Fasting ConditionsBioequivalence Study Healthy Thai VolunteersDonepezil Hydrochloride 10 mg Orodispersible TabletsBioequivalence StudyHealthy Thai Volunteers

TCTR20210121002International Bio Service Co., Ltd.34

尚未招募

1 期

A Single Dose, Randomized, Open-label, Two-way Crossover Bioequivalence Study of Duloxetine 60 mg Hard Gastro-resistant Capsules and Reference Product (Cymbalta) in Healthy Thai Volunteers under Fasting ConditionsBioequivalence Study in Healthy Thai VolunteersDuloxetine 60 mg Hard Gastro-resistant Capsules and Reference Product (Cymbalta) in Healthy Thai Volunteers under Fasting Conditions

TCTR20240701004International Bio Service Co., Ltd.60

尚未招募

1 期

Bioequivalence Study of Entecavir 0.5 mg Film-coated Tablets in Healthy Thai VolunteersHealthy volunteerEntecavir, Bioequivalence Study, Healthy Thai Volunteer

TCTR20210709001International Bio Service Co., Ltd.34